Hta Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Public, Subsidiary
- Established
- 2001-05-18
- Employees
- -
- Market Cap
- -
- Website
- https://www.atom-hitech.com
Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
Phase 3
Recruiting
- Conditions
- Prostate Cancer
- Interventions
- Drug: Florastamin[18F] Injection
- First Posted Date
- 2024-12-31
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- HTA Co., Ltd.
- Target Recruit Count
- 131
- Registration Number
- NCT06754085
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, China
A Phase I Clinical Study on the Safety and Pharmacokinetics of [18F]Florbetazine Injection
- First Posted Date
- 2024-09-12
- Last Posted Date
- 2024-09-12
- Lead Sponsor
- HTA Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT06593626
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
Study of 18F-Florastamin PET/CT Imaging in Patients With at Least Intermediate Risk Prostate Cancer
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- HTA Co., Ltd.
- Target Recruit Count
- 267
- Registration Number
- NCT06011304
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, China
Diagnostic Performance and Safety of 18F-NaF-PET/CT in Bone Metastases Compared With 99mTc⁃MDP-BS±SPECT
Phase 3
Completed
- Conditions
- Bone Metastases
- Interventions
- Drug: Sodium Fluoride F-18 Injection
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- HTA Co., Ltd.
- Target Recruit Count
- 280
- Registration Number
- NCT05614518
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences Peking Union Medical College Hospital, Peking, China
© Copyright 2025. All Rights Reserved by MedPath